Cargando…
A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes
BACKGROUND: Sodium glucose cotransport (SGLT)-2 inhibitors are the newest class of antihyperglycemic agents used as second- or third-line treatment in the management of type 2 diabetes. Although the use of SGLT-2 inhibitors has not been shown to cause nephrotoxicity, there have been case reports of...
Autores principales: | Hassani-Ardakania, Kimya, Lipman, Mark L., Laporta, Denny, Yu, Oriana Hoi Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582856/ https://www.ncbi.nlm.nih.gov/pubmed/31275667 http://dx.doi.org/10.1155/2019/8639629 |
Ejemplares similares
-
Corrigendum to “A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes”
por: Hassani-Ardakani, Kimya, et al.
Publicado: (2021) -
Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice
por: Zhu, Qian, et al.
Publicado: (2023) -
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
por: Yale, J-F, et al.
Publicado: (2013) -
Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
por: Maruyama, Takashi, et al.
Publicado: (2019) -
Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)